Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Zimura + Eylea in IPCV
NCT03374670Phase 2Withdrawn
- Sponsor
- IVERIC bio
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
A Phase 2 trial of avacincaptad pegol in polypoidal choroidal vasculopathy (PCV), sponsored by IVERIC bio. Planned start Nov 2018; status: withdrawn.
02
Drugs
avacincaptad pegol
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT03374670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374670.